"The US Food and Drug Administration (FDA) today approved asfotase alfa (Strensiq, Alexion Pharmaceuticals) as the first-ever therapy for patients who develop hypophosphatasia, a rare metabolic bone disorder, in childhood.
None.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 8/18/2014
Additional Lumizyme Information
Report Problems to the Food and Drug Administration
Find out what women really need.